"Creativity, Persistence Are Key to Advancing the Approach to MS Symptom Management" - Matt Hoffman
Over the past decade, the conversation in multiple sclerosis has been dominated by the influx of available disease-modifying therapies. Now, more than a dozen therapies brought to the market successfully have been a bright light for patients and physicians. According to Fred Lublin, MD, professor of neurology at the Icahn School of Medicine at Mount Sinai, symptomatic therapy in MS is radically different in a strategic sense from what physicians do with DMTs. With the therapies intent on altering disease progression, MS specialists essentially prescribe, then wait and see. With symptom treatment, it’s a much more rapid process. He added, “But then the onus is on the clinician. You’ve got to keep actively working with the patient for dosing.”
— Fred Lublin, MD, Professor, Neurology, Icahn School of Medicine at Mount Sinai, Director, Corrine Goldsmith Dickinson Center for Multiple Sclerosis, Mount Sinai Health System
New Study Details The Various Ways Patients with Multiple Sclerosis Develop Impairment
Feb 22, 2022 View All Press Releases
Two Mount Sinai Experts Receive Honors From the National Multiple Sclerosis Society
Sep 16, 2021 View All Press Releases